CamStent Ltd Collaboration with the University of Nottingham
Kiran Suain Nottingham 13.05.19
Current Affairs Society, University of Nottingham
|
The University of Nottingham and CamStent Ltd have been shortlisted in the Times Higher Education Awards in the Most Innovative Contribution to Business-University Collaboration Category. This collaboration has also been shortlisted in the Knowledge Exchange and Impact Awards for the Faculty of Science award.
These award shortlisting’s are product of the hard work conducted by the School of Pharmacy and Life Sciences at the University of Nottingham in discovering the bacteria resistant material in 2012. Since then, in conjunction with CamStent Ltd, the materials discovered have been further developed to coat medical devices. For example, Foley catheters. The thought process behind the devices being to reduce the risk of bacterial urinary tract infections as the materials within catheters are bacteria resistant, hence cannot grow. The medical device coated with the discovered bacterial resistant materials received approval for trials on humans in April 2018. The new urinary catheters have been awarded a CE mark which means that they align with EU directives regarding health and safety. This has meant that progression has been able to continue, and the specially coated catheter has approved use in hospitals within the UK and the EU. This is a huge step towards reducing the risk of hospital acquired urinary tract infections and has the potential to reduce healthcare complications in patients. CamStent Ltd are a Biotechnology and Medical device company. In conjunction with the University of Nottingham they have enhanced and developed the methods of material coating for consumable medical devices, such as catheters, plastic tubing and stents. Their first commercial product is the foley catheter. This research has been funded by the Wellcome Trust, and continues at the University of Nottingham to understand why the newly discovered materials work. The research and process of understanding this medical innovation is now entering the final phases. The discovery of the new bioresistant materials was also funded by Wellome, through the technique of high throughput micro arrays. The Wellcome Trust is a UK based biomedical research charity. They fund the research within the UK and internationally with the aim of protecting and improving health. Collective Equity Ownership Ltd. (CEO) is a secondary fund. We allow founders and shareholders of VC-backed companies to pool together their shares with other late-stage companies to diversify their portfolio. If you know any cool founders, or someone with a lot of VC experience, get in touch! We love meeting new people! ceo@collectiveequity.com |
Other Viewers have also read:
Artificial Intelligence
|
What is innovation?
|
An interview with Olivia Sibony
|